The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:2647-2648 June 23, 2005 Number 25
NextNext

Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Sabatine, M. S.
-PubMed Citation
To the Editor: Sabatine et al. (March 24 issue)1 demonstrated in the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)–Thrombolysis in Myocardial Infarction (TIMI) 28 trial that clopidogrel added to aspirin, heparin, and thrombolytic therapy for myocardial infarction with ST-segment elevation reduced the composite end point of TIMI grade 0 or 1 flow, death from any cause, or recurrent myocardial infarction. However, the benefit in terms of this composite end point was driven by the greater TIMI flow grade achieved in the clopidogrel group than in the placebo group; there were no differences between the groups in the rates of the clinical . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.